Drugs / AK138D1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07281326 | Oct 2025 → Oct 2026 expected | — | Akeso | Recruiting | No outcome recorded |
| Phase 1 | NCT06730386 | Feb 2025 → Feb 2028 expected | solid adenocarcinoma with mucin production | Akeso | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07623356 | Jun 2026 → Jun 2028 expected | non-small cell lung carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07560124 | Jun 2026 → Jun 2028 expected | breast cancer | Akeso | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Akeso | Regulatory IO2.0+ADC2.0系列疗法组合II期临床开展！康方AK146D1及AK138D1联合卡度尼利/依沃西及自研高潜力药物治疗实体瘤 akesobio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-28 | Akeso | IO2.0+ADC2.0 战略| 康方新一代差异化HER3 ADC(AK138D1)联合依沃西治疗NSCLC的 II 期研究首例入组 akesobio.com ↗ |
| 2026-03-24 | Akeso | IO2.0+ADC2.0系列疗法组合II期临床开展！康方AK146D1及AK138D1联合卡度尼利/依沃西及自研高潜力药物治疗实体瘤 akesobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK138D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623356 ↗ |
| Route | Intravenous | “Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.” NCT06730386 ↗ |